ICH Q13 Continuous Manufacturing: The Control Strategy Element Teams Under-Scope

ICH adopted Q13: Continuous Manufacturing of Drug Substances and Drug Products at Step 4 on November 16, 2022; FDA published it as final guidance for industry the following March. Q13 is not a new topic that needs introducing to most CMC teams anymore — it is a specification most teams still under-read. The section of a filing that most often falls short is not process description or equipment design. It is the one Q13 treats as its own control-strategy element: material traceability and diversion.

What Q13 actually changed

Before Q13, sponsors developed CM programs against FDA's 2019 draft guidance and case-by-case scientific advice, region by region, with no single harmonized reference. Q13 consolidated that into one guideline spanning four annexes — continuous manufacturing of drug substance for chemical entities, drug product for chemical entities, drug substance for therapeutic proteins, and integrated drug substance/drug product lines. That is a harmonization step, not a loosening of expectations: the guideline is explicit that Q13 builds on the control-strategy language in ICH Q8, Q9, and Q10 rather than substituting for it. Work that used to sit inside regulatory CMC strategy and commissioning, qualification, and validation as separate conversations now has one reference point tying them together.

The control strategy is the filing

Q13's control-strategy expectations are not a checklist bolted onto a batch-era submission. They are the argument that the process holds a defined state of control, built from several elements that have to work together rather than appear as separate sections:

• Process design and the state of control. What “in control” means for this specific line, defined before the equipment description — not inferred from it.
• Process dynamics characterization. Residence time distribution and how a disturbance or an out-of-spec input propagates — and is traced — through the line.
• Material characterization and control. How incoming material variability is controlled and monitored continuously, not sampled at intervals designed for batch processing.
• Real-time release testing (RTRT). A validated combination of in-process measurement and model that substitutes for end-product testing — and has to be maintained as a validated system, not a one-time study.
• Material traceability and diversion. How input material lots map to time- or quantity-based output segments, and the documented, risk-based basis for diverting a nonconforming segment without halting the run.
• Pharmaceutical quality system oversight. The control strategy is a living document under the quality system, updated through ICH Q12 lifecycle management as the process or its risk assessment changes.

A continuous line does not produce batches by default. It produces a state of control — and traceability and diversion are how you prove a deviation stayed inside it. Why traceability and diversion carries the submission risk

Where filings fall short

The recurring gap is not the science — it is scope. Teams port a batch-era traceability approach onto a CM line, describing the entire run as one lot rather than defining the time- or quantity-based segments Q13 expects and the risk-based rationale, grounded in ICH Q9(R1) quality risk management, for diverting any one of them. RTRT models get validated once during development and are never revisited against the guidance's lifecycle-management expectations. And the control-strategy narrative itself often reads as an equipment and process description — solid engineering writing that never states, in terms a CMC reviewer is looking for, what a deviation from the state of control would look like and how the line would catch it.

None of this requires new science. It is a bounded piece of documentation and process-design work: a state-of-control definition, a traceability and diversion plan with a genuine risk basis, an RTRT lifecycle plan, and a control strategy written to be read by a CMC reviewer rather than an equipment vendor. Programs that treat Q13 as a section to restate get queried on exactly the element they restated most thinly. Programs that treat it as the specification for what the filing has to prove are the ones that move through review without a traceability or diversion deficiency.